Global Allergy Diagnostics and Therapeutics Market: USD 34.65 Billion in 2025 to USD 62.94 Billion b

Author : pratiksha mmr | Published On : 13 Aug 2026

Global Allergy Diagnostics and Therapeutics Market: USD 34.65 Billion in 2025 to USD 62.94 Billion by 2032 at 8.9% CAGR.

Global Allergy Diagnostics and Therapeutics Market is moving into a high-innovation growth cycle as rising allergic disease prevalence, advanced diagnostic technologies, pharmaceutical innovation and patient-centric healthcare converge. According to Maximize Market Research, the market was valued at USD 34.65 billion in 2025 and is projected to reach USD 62.94 billion by 2032, expanding at a CAGR of 8.9% during 2026–2032. The expansion is being supported by increasing allergic conditions, healthcare infrastructure development, rising awareness, growing disposable income, an expanding geriatric population and increasing R&D activity.

Request a Free Sample of Full Market Report Link: https://www.maximizemarketresearch.com/request-sample/99881/

Allergy Care Enters the Precision Healthcare Era

Allergy management is evolving from conventional symptom control toward earlier identification, targeted diagnostics and more personalized therapeutic pathways. Increasing pollution, rapid urbanization, changing lifestyles and the growing prevalence of respiratory disorders are intensifying demand for allergy testing and treatment solutions. MMR also identifies healthcare infrastructure expansion and regulatory and industry initiatives aimed at increasing allergy awareness as important market-supporting factors.

The transformation is particularly relevant for hospitals, diagnostic laboratories and research centers seeking faster, more reliable and increasingly patient-centric diagnostic workflows.

Get Free Sample of Full Market Report Link: https://www.maximizemarketresearch.com/market-report/global-allergy-diagnostics-and-therapeutics-market/99881/

Market Segmentation: Key Growth Engines

By Allergen Type: Inhaled Allergens, Food Allergens, Drug Allergens, Others
By Product: Instruments, Consumables, Luminometers
By Tests: In Vivo, In Vitro
By End User: Hospitals, Diagnostic Laboratories, Research & Development Centers, Others
By Region: North America, Europe, Asia Pacific, Middle East & Africa, South America

Inhaled allergens are expected to dominate the allergen-type segment, supported by pollution and changing lifestyles. Within testing, in-vivo testing is expected to retain the largest share, while MMR identifies in-vitro testing as an attractive growth area because of demand for less-invasive diagnostics, sensitivity and reliable results.

AI-Powered Diagnostics and Biotechnology Reshape Allergy Detection

The next-generation allergy diagnostics market is increasingly aligned with the broader AI-driven healthcare movement. Automated image interpretation, digital laboratory workflows, connected diagnostic platforms and data-enabled clinical decision support can improve consistency and accelerate allergy assessment.

Research published in 2025 demonstrated an automated approach for detecting and delineating allergy-related wheals from skin-prick-test images using neural-network technology, highlighting the potential for computer-assisted allergy diagnostics.

Meanwhile, the broader biotechnology ecosystem is attracting investment into AI-enabled diagnostics and precision medicine, creating opportunities for allergy companies to integrate advanced analytics with laboratory and clinical data.

Pharmaceutical Innovation Accelerates Therapeutic Options

Therapeutic innovation is becoming a defining force. In February 2024, the U.S. FDA approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis risk, after accidental exposure to one or more foods in eligible patients with IgE-mediated food allergy. It represented the first FDA-approved medication for reducing reactions to multiple food allergens after accidental exposure.

The innovation pipeline continued in 2025, when the FDA listed Omlyclo (omalizumab-igec) among newly approved interchangeable biosimilars for indications including IgE-mediated food allergy.

In India, MMR reports that Sanofi introduced Allegra-D in August 2025, following approval by the Drug Controller General of India for adults and adolescents aged 12 years and above.

These developments point toward a market where biologics, immunotherapy, biosimilars and combination therapies increasingly complement traditional allergy medicines.

Regional Outlook: Seven Strategic Healthcare Markets

USA: North America held the dominant market share in 2022 and is expected to maintain leadership through the forecast period, supported by respiratory allergy prevalence, awareness and adoption of in-vitro blood testing.

UK: The United Kingdom represents an important European market within MMR's country-level analysis, supported by established healthcare and pharmaceutical capabilities.

Germany: Germany's mature pharmaceutical ecosystem and advanced healthcare infrastructure position it as a significant European opportunity for diagnostics and therapeutics.

Japan: Japan's advanced medical technology environment and established healthcare infrastructure support opportunities for sophisticated allergy diagnostics and treatment.

South Korea: South Korea's technology-oriented healthcare ecosystem creates opportunities for digital diagnostics, laboratory automation and connected clinical workflows.

China: China is a key Asia Pacific market covered by MMR, with expanding healthcare infrastructure and increasing demand for advanced diagnostic and therapeutic technologies.

India: India presents significant long-term opportunity amid rising healthcare expenditure, allergy awareness, urbanization and pharmaceutical development. MMR specifically identifies India within its detailed Asia Pacific market assessment.

Beyond these markets, MMR covers Canada, Mexico, France, Italy, Spain, Sweden, Australia, ASEAN markets, Brazil and other emerging economies. Asia Pacific is highlighted as a major future hotspot because of regional R&D activity, technology availability and expanding healthcare needs.

Competitive Landscape: Building the Next Allergy Ecosystem

MMR profiles leading participants including Thermo Fisher Scientific, Siemens Healthineers, Danaher, bioMérieux, Eurofins Scientific, Stallergenes Greer, ALK-Abelló, Omega Diagnostics, HYCOR Biomedical, R-Biopharm, HAL Allergy Group, Novartis, Bayer, Pfizer, Sanofi, GSK, AstraZeneca, Abbott Laboratories, Merck KGaA and Quest Diagnostics, among others.

Competition is increasingly shifting toward diagnostic accuracy, therapeutic differentiation, biotechnology platforms, regulatory capabilities and integrated patient journeys.

Future of Lifesciences: From Testing to Intelligent Allergy Management

The Global Allergy Diagnostics and Therapeutics Market is positioned at the intersection of precision medicine, biotechnology innovation, smart diagnostics and digital healthcare transformation. AI-assisted testing, in-vitro diagnostics, immunotherapy, biologics, biosimilars and connected healthcare infrastructure can redefine how allergies are identified and managed.

For investors, diagnostic manufacturers, pharmaceutical companies and healthcare providers, the opportunity extends beyond individual products toward integrated ecosystems spanning diagnostics, therapeutics, clinical research and patient monitoring.

Maximize Market Research provides strategic market intelligence to help healthcare and life-science organizations evaluate investment priorities, emerging technologies, competitive positioning and regional expansion opportunities. Stakeholders seeking strategic insights, healthcare investment analysis and regional opportunity mapping can use MMR's research to identify the next growth pathways in the rapidly evolving Global Allergy Diagnostics and Therapeutics Market.

Allergy Diagnostics and Therapeutics Market https://www.maximizemarketresearch.com/request-sample/99881/

Systemic Inflammatory Response Syndrome Treatment Market https://www.maximizemarketresearch.com/request-sample/36090/

Laboratory Plasticware Market https://www.maximizemarketresearch.com/request-sample/90034/

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

2nd Floor, Navale IT Park Phase 3
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India
+91 9607365656
[email protected]